NCT02174510View on ClinicalTrials.gov

A Pharmacokinetic Study of Lurasidone After Single Oral Administration in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

March 31, 2014

Primary Completion Date

April 30, 2014

Study Completion Date

April 30, 2014

Conditions
Schizophrenia
Interventions
DRUG

20mg lurasidone

single oral lurasidone or placebo in 30 minutes after beginning of the over 350 kcal breakfast on day 1.

DRUG

40mg lurasidone

single oral lurasidone or placebo in 30 minutes after beginning of the over 350 kcal breakfast on day 1.

DRUG

80mg lurasidone

single oral lurasidone or placebo in 30 minutes after beginning of the over 350 kcal breakfast on day 1.

DRUG

placebo

Trial Locations (1)

200031

Xuhui Center Hospital, Shanghai

All Listed Sponsors
collaborator

Xuhui Central Hospital, Shanghai

OTHER

lead

Sumitomo Pharma (Suzhou) Co., Ltd.

INDUSTRY

NCT02174510 - A Pharmacokinetic Study of Lurasidone After Single Oral Administration in Healthy Subjects | Biotech Hunter | Biotech Hunter